NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
WULF
TeraWulf Inc.
There isn't enough reported data to score WULF yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
WULF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| N/A | |
| N/A |
WULF's revenue is currently healthy, but its profitability is weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like WULF.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
WULF PE Valuation
WULF has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
WULF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect WULF's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over WULF on earnings quality, reporting a profit while its opponent remains loss making.
WULF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.30 | -$1.87 |
| Q2 2026 | -$4.40 | -$4.04 |
| Q1 2026 | -$2.51 | -$2.17 |
| Q4 2025 | -$1.66 | -$1.45 |
| Q3 2025 | -$1.43 | -$1.29 |
| Q2 2025 | -$0.36 | -$0.19 |
| Q1 2025 | -$0.34 | -$0.12 |
| Q4 2024 | -$0.21 | +$0.14 |
WULF lost $3.30 per share over the past year, a bigger loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over WULF on profitability, with a higher operating margin.
WULF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $76.2M | +51% |
| Q2 2026 | $44.8M | -6% |
| Q1 2026 | $34M | -1.1% |
| Q4 2025 | $35.8M | +2.4% |
| Q3 2025 | $50.6M | +87% |
| Q2 2025 | $47.6M | +34% |
| Q1 2025 | $34.4M | -19% |
| Q4 2024 | $35M | +50% |
WULF's revenue is growing: $76M last quarter, up 51% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -116% | -67 points |
| Q2 2026 | -314% | -281 points |
| Q1 2026 | -477% | -303 points |
| Q4 2025 | -241% | -94 points |
| Q3 2025 | -49% | +9.3 points |
| Q2 2025 | -33% | -14 points |
| Q1 2025 | -173% | -168 points |
| Q4 2024 | -147% | -127 points |
WULF's operating margin was −116% last quarter, down 67 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over WULF on cash generation, producing positive trailing cash flow while its opponent burns cash.
WULF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$876.9M | -$608.7M |
| Q2 2026 | -$992.3M | -$817.5M |
| Q1 2026 | -$540.5M | -$503.3M |
| Q4 2025 | -$703.2M | -$506.8M |
| Q3 2025 | -$268.3M | -$226.6M |
| Q2 2025 | -$174.8M | -$144.5M |
| Q1 2025 | -$37.2M | -$13.1M |
| Q4 2024 | -$196.4M | -$173.5M |
WULF's free cash flow was −$3.1B over the past year, against −$677M the year before. Free cash flow isn't a meaningful measure for financial services companies like WULF.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over WULF on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
WULF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +18% | +87.9M shares |
| 1 year | +43% | +172M shares |
| 3 years | +173% | +363M shares |
| 5 years | +28923% | +572M shares |
| Available history | +28866% | +572M shares |
WULF has 574M diluted shares, up 43% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $33.3M |
| Q4 2021 | — |
WULF hasn't bought back shares in the past year.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
WULF Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -1.0x | Net Cash |
| Q2 2024 | -1.4x | Net Cash |
| Q1 2024 | 3.5x | Elevated |
| Q4 2021 | 32.9x | High |
WULF has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like WULF.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
WULF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.6 | Neutral |
| Stochastic | 24.3 | Neutral |
WULF's weekly RSI is 41 (neutral) and its Stochastic is 24 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
WULF PE vs Financial Services Sector
| Metric | WULF | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
WULF has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
WULF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.0 | 0.2% above |
| 20 week MA | $15.9 | 18% below |
| 50 week MA | $17.1 | 24% below |
| 100 week MA | $11.9 | 9.7% above |
| 200 week MA | $7.29 | 79% above |
WULF has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
WULF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.42 | $6.48 | +20% |
| 2021 | $6.48 | $14.4 | +122% |
| 2022 | $14.4 | $0.77 | -95% |
| 2023 | $0.77 | $2.40 | +212% |
| 2024 | $2.40 | $5.53 | +130% |
| 2025 | $5.53 | $11.8 | +112% |
| 2026 YTD | $11.8 | $13.0 | +11% |
WULF has the edge over NVO on returns for 2026, with the stronger performance.